ERBB2 and breast carcinoma: Research by Lui et al., (2018) [177] showed that knockdown of both WIP1 and miR-21, reduced proliferation, survival, and tumorigenic potential of HER2-positive breast cancer cells harboring 17q23 amplification, thus, providing an effective therapeutic strategy for HER2-positive breast cancers [177].